Prame as a secondary target for BCR-ABL-positive leukemias (2006)
- Authors:
- USP affiliated authors: CARVALHO, DERMEVAL DE - FCFRP ; CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; ZAGO, MARCO ANTONIO - FMRP ; MENDES, JOAO GUSTAVO PESSINI AMARANTE - ICB
- Unidades: FCFRP; FMRP; ICB
- Subjects: LEUCEMIA; EXPRESSÃO GÊNICA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Haematologica
- ISSN: 0390-6078
- Volume/Número/Paginação/Ano: v. 91, suppl. 1, p. 249-250, res. 0677, 2006
- Conference titles: Congress of The European Hematology Association
-
ABNT
CARVALHO, Dermeval de et al. Prame as a secondary target for BCR-ABL-positive leukemias. Haematologica. Pavia: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 23 abr. 2024. , 2006 -
APA
Carvalho, D. de, Proto-Siqueira, R., Leroy, J. M. G., Pereira, W. O., Zanichelli, M. A., Colassantti, M. D., et al. (2006). Prame as a secondary target for BCR-ABL-positive leukemias. Haematologica. Pavia: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. -
NLM
Carvalho D de, Proto-Siqueira R, Leroy JMG, Pereira WO, Zanichelli MA, Colassantti MD, Camanho D, Alves DIC, Zago MA, Castro FA de, Amarante-Mendes JGP. Prame as a secondary target for BCR-ABL-positive leukemias. Haematologica. 2006 ; 91 249-250.[citado 2024 abr. 23 ] -
Vancouver
Carvalho D de, Proto-Siqueira R, Leroy JMG, Pereira WO, Zanichelli MA, Colassantti MD, Camanho D, Alves DIC, Zago MA, Castro FA de, Amarante-Mendes JGP. Prame as a secondary target for BCR-ABL-positive leukemias. Haematologica. 2006 ; 91 249-250.[citado 2024 abr. 23 ] - Prame as a secondary target for Bcr-Abl-positive leukemia
- BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
- Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide
- Development and characterization of murine models of T lymphoma to investigate the impact of oncogene expression
- Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells
- T lymphoma murine models to study the impact of ectopic expression of anti-apoptotic oncogenes
- BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia
- Study of pro and anti-apoptotic genes to understand the resistance of apoptosis mediated by Bcr-Abl
- PRAME expression is associated with down-regulation of trail in chronic myeloid leukemia
- BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
